Damora Therapeutics, Inc.(DMRA)
Biotechnology
Oncology Biotech
| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership changeShares owned | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-07 | Winslow Garrett General Counsel | Sale | -245 | -1.21%19,956 | $29.98 | $7,345 | View SEC filing | |
| 2026-01-06 | Schambye Hans T. Chief Executive Officer | Sale | -700 | -13.01%4,682 | $21.38 | $14,966 | View SEC filing | |
| 2026-01-06 | Winslow Garrett General Counsel | Sale | -255 | -12.09%1,854 | $21.38 | $5,452 | View SEC filing | |
| 2026-01-06 | Firmani Lori Chief Financial Officer | Sale | -135 | -12.66%931 | $21.41 | $2,890 | View SEC filing | |
| 2025-07-08 | Schambye Hans T. Chief Executive Officer | Sale | -735 | -15.45%4,022 | $3.38 | $2,484 | View SEC filing | |
| 2025-07-08 | Winslow Garrett General Counsel | Sale | -260 | -15.39%1,429 | $3.39 | $881 | View SEC filing | |
| 2025-07-08 | Firmani Lori Interim CFO | Sale | -147 | -17.52%692 | $3.39 | $498 | View SEC filing | |
| 2025-01-07 | Winslow Garrett General Counsel | Sale | -471 | -31.82%1,009 | $5.60 | $2,638 | View SEC filing | |
| 2025-01-07 | Firmani Lori Interim CFO | Sale | -261 | -35.95%465 | $5.63 | $1,469 | View SEC filing | |
| 2025-01-07 | Schambye Hans T. Chief Executive Officer | Sale | -1,341 | -28.30%3,397 | $5.60 | $7,510 | View SEC filing | |
| 2023-08-17 | ORBIMED ADVISORS LLC 10% Owner | Sale | -822,680 | +1014.41%1,510,375 | $0.75 | $617,010 | View SEC filing | |
| 2023-08-02 | ORBIMED ADVISORS LLC 10% Owner | Sale | -209,400 | +1198.72%2,105,909 | $3.00 | $628,200 | View SEC filing | |
| 2023-07-27 | ORBIMED ADVISORS LLC 10% Owner | Sale | -39,200 | +1229.18%2,258,987 | $2.92 | $114,464 | View SEC filing | |
| 2023-07-17 | ORBIMED ADVISORS LLC 10% Owner | Sale | -194,700 | +1171.57%2,285,687 | $2.40 | $467,280 | View SEC filing | |
| 2023-04-17 | ORBIMED ADVISORS LLC 10% Owner | Sale | -68,481 | +1219.70%2,417,787 | $1.87 | $128,257 | View SEC filing | |
| 2023-04-12 | ORBIMED ADVISORS LLC 10% Owner | Sale | -67,537 | +1207.33%2,464,234 | $1.80 | $121,357 | View SEC filing | |
| 2023-04-07 | ORBIMED ADVISORS LLC 10% Owner | Sale | -102,630 | +1208.76%2,510,041 | $2.16 | $221,994 | View SEC filing | |
| 2022-03-23 | Lindmark Bertil Chief Medical Officer | Purchase | +14,604 | +730.20%16,604 | $2.16 | $31,545 | View SEC filing | |
| 2022-03-23 | Schambye Hans T. Chief Executive Officer | Purchase | +5,000 | +10.54%52,428 | $2.15 | $10,750 | View SEC filing | |
| 2021-12-06 | Winslow Garrett General Counsel | Purchase | +2,000 | +100.00%4,000 | $2.48 | $4,960 | View SEC filing | |
| 2021-12-06 | Freve Jonathan Chief Financial Officer | Purchase | +4,000 | +50.00%12,000 | $2.49 | $9,960 | View SEC filing | |
| 2021-11-10 | Schambye Hans T. Chief Executive Officer | Purchase | +4,500 | +10.48%47,428 | $3.50 | $15,750 | View SEC filing | |
| 2021-11-09 | Freve Jonathan Chief Financial Officer | Purchase | +3,000 | +60.00%8,000 | $3.40 | $10,200 | View SEC filing | |
| 2021-08-19 | Freve Jonathan Chief Financial Officer | Purchase | +3,000 | +150.00%5,000 | $3.92 | $11,760 | View SEC filing | |
| 2021-06-28 | Lindmark Bertil Chief Medical Officer | Purchase | +2,000 | +100.00%2,000 | $5.26 | $10,520 | View SEC filing |
1-25 of 32